AGC Biologics to Supply More Plasmid DNA for Pfizer-BioNTech COVID-19 Vaccine

BioPharm International Editors

AGC Biologics has partnered with BioNTech to further supply plasmid DNA starting material from its Heidelberg, Germany, facility for the Pfizer-BioNTech COVID-19 vaccine.

On June 7, 2021, AGC Biologics, a contract development and manufacturing organization (CDMO), announced that it has partnered with BioNTech to further supply plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at AGC’s Heidelberg, Germany, facility. pDNA starting material is an essential component of BioNTech’s mRNA-based vaccine manufacturing process.

“We are honored that BioNTech has entrusted us to become part of their global supply network in an effort to make the vaccine available to as many people as possible around the world,” said Mark Womack, AGC Biologics’ chief business officer, in a company press release. “We are very proud of our efforts to provide our global customers with the essential materials needed to rapidly deliver vaccines in the fight against the COVID-19 pandemic.”

“The team at Heidelberg is enthusiastically embracing this important project with BioNTech,” said Dieter Kramer, AGC Biologics’ general manager, Heidelberg, in the press release. “[We] look forward to supporting BioNTech in the production of their mRNA-based COVID-19 vaccine with [p]lasmid DNA.”

Source: AGC Biologics